Phreesia (PHR) – Analysts’ Recent Ratings Changes

Phreesia (NYSE: PHR) has recently received a number of price target changes and ratings updates:

• 4/1/2026 – Phreesia had its “market perform” rating reaffirmed by Citizens Jmp.
• 3/31/2026 – Phreesia had its price target lowered by Stephens from $32.00 to $20.00. They now have an “overweight” rating on the stock.
• 3/31/2026 – Phreesia had its price target lowered by BMO Capital Markets from $32.00 to $14.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Phreesia had its price target lowered by Canaccord Genuity Group Inc. from $33.00 to $22.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by JPMorgan Chase & Co.. They now have a $16.00 price target on the stock, down from $24.00.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $10.00 price target on the stock, down from $25.00.
• 3/31/2026 – Phreesia had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $11.00 price target on the stock, down from $24.00.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $10.00 price target on the stock, down from $25.00.
• 3/31/2026 – Phreesia had its price target lowered by Needham & Company LLC from $35.00 to $14.00. They now have a “buy” rating on the stock.
• 3/26/2026 – Phreesia had its price target lowered by Wells Fargo & Company from $30.00 to $25.00. They now have an “overweight” rating on the stock.
• 3/24/2026 – Phreesia had its price target lowered by Mizuho from $22.00 to $19.00. They now have an “outperform” rating on the stock.
• 2/20/2026 – Phreesia had its price target lowered by JPMorgan Chase & Co. from $29.00 to $24.00. They now have an “overweight” rating on the stock.
• 2/8/2026 – Phreesia was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/4/2026 – Phreesia was given a new $22.00 price target by Mizuho.

Insider Buying and Selling

In other news, insider Evan Roberts sold 6,268 shares of Phreesia stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $102,544.48. Following the sale, the insider owned 826,554 shares of the company’s stock, valued at $13,522,423.44. The trade was a 0.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Linetsky sold 6,038 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $98,781.68. Following the transaction, the insider owned 223,942 shares in the company, valued at approximately $3,663,691.12. This trade represents a 2.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 70,358 shares of company stock worth $1,123,569. 5.50% of the stock is currently owned by insiders.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.